EHMT2 and cancer: They have emerged as therapeutic targets as this process modulates transcription[61] and its dysregulation is implicated in numerous forms of cancer.[62] Euchromatic histone methyltransferase 2, otherwise known as G9a, is an example of such an HMT which has been linked to various cancers.[63] Sweis et al.[64] searched for chemically distinct G9a inhibitors through screening of an in‐house compound library.